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ABSTRACT                        Medical application of ionizing radiation and radioactive isotopes were consid-
ered almost immediately after their discovery. The intense research interest in radioactivity, 
materials structure, subatomic particles and in the establishment of physical principles resulted 
in milestone inventions such as the radiotracer principle, particle accelerators, nuclear reactors 
and detectors sensitive enough to indicate different types of radiations even at very low intensi-
ties. This technical development together with advancements in pharmaceutical chemistry led 
to the establishment of nuclear medicine as a new discipline, and currently the prevalence of 
radiologic applications in today’s medicine is obvious as tens of millions of nuclear medicine 
procedures are performed annually in more than 10,000 hospitals worldwide (World Nuclear 
Association 2014). In this review a brief historical outline of the most important discoveries 
and a summary of principles of radioactivity and radioactivity detection are given. Diagnostic 
and therapeutic application of radiopharmaceuticals, their production and their tissue-specific 
targeting methods are also discussed along with an introduction of state-of-the-art diagnostic 
modalities and a summary of further requirements and future perspectives.
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Introduction
In 1895 Wilhelm Conrad Röntgen observed a unique electro-
magnetic radiation called X-rays. Later, in 1896 Henry Bec-
querel discovered natural radioactivity when he took the first 
image of a natural radioactive substance, zippeite. These basic 
observations initiated intense research concerning radioactiv-
ity, materials structure and subatomic particles. Today, tens of 
millions of nuclear medicine procedures are performed annu-
ally in more than 10,000 hospitals worldwide. Different types 
of radiations originated from radioactive decay are exploited 
by nuclear medicine to provide diagnostic information of the 
patients and to treat them. Indeed, nuclear medicine is one of 
the most sensitive methods today for obtaining information on 
physiological functions. The most common radioisotope for 
diagnosis is Tc-99m, with ca. 30 million applications per year, 
accounting for 80-90% of all nuclear medicine procedures 
(World Nuclear Association 2014). Radiotherapy is mainly 
used to treat different types of cancers by the specific destruc-
tion of malignant cells. Milestone discoveries of this rapid 
scientific and technological development are reviewed, and an 
overview of radiopharmaceutical applications is presented.
development of nuclear medicine
Soon after the discovery of X-rays, their practical applica-
tion in research and imaging became apparent. It was also 
observed that prolonged exposure to X-rays produced in-
flammation and tissue damage on the skin, which led to the 
application of irradiation in the treatment of skin diseases 
(Pusey 1900). After unambiguous X-ray therapeutic trials, 
Henry Coutard had developed a fractionated process that is 
the basis for current radiation therapy (Coutard 1937). Two 
years after Becquerel’s discovery, Marie and Pierre Curie 
discovered two natural radioactive elements, Po-210 and 
Ra-226. The radiation of the latter one was immediately 
suggested to use in the therapy of skin lesion, and it was the 
first natural radioactive substance used in human medicine. 
The widespread medical applications of radioisotopes be-
came feasible after the discovery of the radiotracer method 
by György Hevesy, the invention of the cyclotron by Ernest 
O. Lawrence and the discovery of artificial radioactivity by 
Irène Curie and Frédérick Joliot.
Hevesy recognized that the chemical properties of a com-
pound and its isotopologues were identical, and consequently 
a radioactive atom might be used as a tracer of stable atoms 
of the same element in biological systems. A radiotracer is 
a compound containing one or more radioactive isotopes, 
and measuring the radioactivity of the tracer resulted in 
increased sensitivity and accuracy over existing methods. 
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Hevesy described the radioactive tracer concept in 1913 
and introduced it in life sciences (Hevesy 1923). In 1925, 
Hermann Blumgart performed the first human radiotracer 
experiment to study the cardiovascular system (Patton 2003). 
The diagnostic radiopharmaceutical prepared by Blumgart’s 
procedure was a saline solution of Pb-214 and Bi-214 (Fig. 
1). The Wilson cloud chamber modified by Shimizu (Shimizu 
1921) and Yens (Blumgart et al. 1926) became the detector of 
choice, appropriate for dynamic detection in the circulating 
system. The optimized method required minimal cooperation 
of the patient and it was objective, noninvasive, and rapid 
enough to automatically detect the previously administered 
radioactive substance. The radioactive tracer was applied in 
a minute amount therefore it had no pharmacological effect. 
It highlighted the most important characteristic of a tracer, 
i.e. it can facilitate the study of components of a homeostatic 
system without disturbing their function.
Subatomic particles important for practical nuclear medi-
cine (electron (Thomson 1897), proton (Rutherford 1919) 
and neutron (Chadwick 1932)) had also been discovered 
this period of time. Another important particle, the positron 
postulated in 1928 by Paul Dirac was first observed in 1932 
by Carl D. Anderson (Anderson 1932).
Rutherford demonstrated the first artificial production of 
O-17 by bombarding N-14 with α particles, that was followed 
by the work of Frédérick Joliot and Irène Curie who achieved 
the first production of a radioactive isotope (Joliot et al. 1934). 
They investigated the bombardment of light elements with Po 
derived α particles, and they observed that in the case of Al 
the target remained active after the bombardment stopped. 
The radionuclide was identified as P-30 that decayed to Si-30. 
Before this groundbreaking discovery, Leó Szilárd filed two 
patents in Germany on a linear accelerator and on a cyclotron 
in 1928 and 1929, respectively, but they were never published. 
The development of the cyclotron, a device that makes it 
possible to produce larger amount of artificial radionuclides 
was first described by Earnest O. Lawrence and his students 
(Lawrence et al. 1932). By 1936 up to 200 radionuclides had 
been produced, and at present ca. 2500 isotopes are known 
among which there are up to 200 radioisotopes regularly used 
and mainly produced artificially.
The discovery of the cyclotron produced artificial radioac-
tivity opened the way to the production of a variety of radio-
indicators useful for medical purposes. The phosphorous 
metabolism and cellular processes involving phosphorous 
containing molecules had pioneered by the work of Gy. 
Hevesy and O. Chiewitz. For their early experiments they 
used carbon disulfide to absorb neutrons emitted from a Ra-
Be mixture, and then the aqueous extract containing P-32 was 
applied for life science studies (Chiewitz et al. 1935). Later 
P-32 was produced in larger quantities by Lawrence’s cyclo-
tron. Dynamics of sodium transport was investigated with 
Na-24 by J. G. Hamilton (Hamilton et al. 1937). I-128 was 
applied for the study of thyroid physiology (Hertz et al. 1938) 
and later for the diagnosis and treatment of Graves’ disease. 
The adsorption of fluoride by enamel, dentine and bone was 
evidenced by using a F-18 tracer (Volker et al. 1940). The first 
radioactive iodine isotope, I-128 was discovered by E. Fermi 
in 1934, and four years later G. Seaborg discovered I-131. The 
latter one was immediately used for diagnostic purposes by J. 
G. Hamilton. In the 40s’ numerous radioactive tracers were 
introduced in clinical medicine (Marshall 1990), followed by 
a continuous interdisciplinary work of physicists, chemists 
and physicians in order to develop detection instruments and 
radiopharmaceuticals which could be used to investigate (i) 
the underlying mechanisms of human diseases, (ii) the earli-
est manifestation of them in a noninvasive way, and (iii) their 
selective treatment. The detailed review of the evolution of 
nuclear medicine, especially the development of sophisticated 
detectors and computing algorithms in the second half of the 
20th century is far beyond the scope of this review. Instead, the 
birth of the discipline is demonstrated and further important 
milestones are summarized in Table 1.
Principles of radioactivity
Radiopharmaceuticals are radioactive labelled substances 
containing one or more radionuclide(s) suitable for adminis-
tration to humans. The chemical and physical properties of 
the radiopharmaceutical affect its localization in the body, 
while the radioactive decay properties determine the detection 
method and the diagnostic or therapeutic applicability. The 
emission of the diagnostic radionuclides is used to visualize 
the distribution of the labelled substance in the body, and 
that of the therapeutic radionuclides is used to deliver a high 
radiation dose to the target tissue.
The relative stability of nuclei can be compared via the 
binding energy per nucleon (E
B
/A) (Fig. 2). Radioactive 
decay, a spontaneous nuclear transformation is a way for 
nuclides to achieve a more stable nuclear state. The time 
Figure 1. Segment of the decay chain used for the preparation of the first radiopharmaceutical, saline containing Pb-214 and Bi-214.
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dependence of radioactive decay is expressed in terms of 
the half-life (t
1/2
), that varies in a wide range of time with the 
shortest measurable half-life of 10–18 s. Radioactive decay 
involves a transition from a definite quantum state of the 
original nuclide (parent) to a definite quantum state of the 
product nuclide (daughter). The energy difference between 
the two quantum levels corresponds to the decay energy that 
appears in the form of electromagnetic radiation and as the 
kinetic energy of the product particles (Choppin et al. 2002). 
The mode of radioactive decay depends on the particular 
radionuclide. Alpha decay is the emission of a He2+ (α par-
ticle), and with a few exceptions, only radionuclides heavier 
than lead and a few lanthanide elements decay by this way. 
An example is Ra-226 that produces Rn-222 and 4.78 MeV 
α particles. Soon after the discovery of radium, Ra-226 and 
its radioactive daughter Rn-222 were used in medicine. At 
present alpha radiation has no significant clinical usefulness. 
However, some α emitters are investigated for therapeutic ap-
plications, because α particles are the least penetrating type 
of radiation producing dense ionization and severe radiation 
damage within a tissue. Beta decay is the emission of either 
an electron or a positron, or the process of electron capture. 
Neutron-rich radionuclides undergo β– decay resulting in the 
emission of high speed electrons (β–) and antineutrinos with 
kinetic energies ranging up to the maximum value of the de-
cay energy, E
max
. These electrons travel several hundred times 
the distance of α particles in air and require a few millimeters 
of aluminum to absorb them. Positron decay occurs when the 
n/p ratio is too low for stability and a proton is transformed 
into a neutron followed by the ejection of a positron – anti-
neutrino pair. Positrons are emitted with a continuous energy 
distribution but exist only for a very short period of time (ca. 
1 μs), after which they loose most of their kinetic energy and 
combine with an electron. This annihilation results in two 
511 keV photons emitted in opposite directions. Electron 
capture (EC) is another way for proton-rich nuclides to be 
stabilized. The nuclear composition changes similarly to that 
occurring in positron decay, but via a different mechanism: 
the nucleus captures an orbital electron, usually from the K-
shell. Electrons from higher energy levels immediately fill the 
vacancy, and the excess energy of the orbital rearrangement(s) 
is emitted as a secondary radiation of a cascade of charac-
teristic X-ray photons and Auger-electrons. EC and positron 
decay are competing processes, but if the parent proton-rich 
nuclide does not have at least 1.022 MeV of transition energy, 
a positron cannot be formed and only EC will occur. EC is 
advantageous for diagnostic applications because it does 
not produce particulate radiation that lowers the patient’s 
effective dose. The following radionuclides used in nuclear 
medicine decay by EC: Cr-51, Co-57, Ga-67, In-111, I-123, 
I-125 and Tl-201.
The α and β decay may result in daughter nuclei in an 
excited state. When excited nuclei reach their ground state 
the transition energy is released either by electromagnetic 
radiation (γ radiation) or by internal conversion. The release 
1895 X-rays (W.C. Röntgen) 1951 NaI crystals for positron detection (W. Sweet, G. Brownell)
1896 Radioactivity 1953 Cerebral blood flow with Kr-81m (N. Lassen)
1898 Po, Ra, Th (M. S. Curie) 1958 Anger gamma camera (H. O. Anger)
1923 Tracer principle (Gy. Hevesy 1959 Radioimmunoassay (R. S. Yalow, S. Berson)
1928 Gas filled counter (J. W. Geiger, W. Müller) 1962 Tc-99m generator (P. Harper, K. Lathrope)
1932 Cyclotron (E. O. Lawrence) 1962 SPET (D. Kuhl)
1934 I-128 (E. Fermi) 1973 Description of the CT scanner (G. H. Hounsfield)
1936 Tc-99m (E. G. Segre) 1973 First PET tomograph (M. Ter-Pogossian, M. Phelps)
1936 Therapeutic use of P-32 (J. H. Lawrence) 1978 [18F]FDG (T. Ido)
1938 I-131 (G. Seaborg) 1997 FDA approves [18F]FDG as radiopharmaceutical
1946 Thyroid cancer therapy (S. M. Seidlin, L. D. Marinelli) 1998 PET/CT prototype (D. Townsend, R. Nutt)
1949
Thyroid carcinoma therapy in Europe (C. Winkler, E. E. 
Pochin) 2000s
Revolution of hybrid tomographic imaging (PET/CT and 
SPECT/CT); end of 2D planar imaging
1951 Rectilinear scanner (B. Cassen) 2010s
Quantitative 3D imaging on hybrid devices, beginning of 
targeted therapies
Table 1.  Development of nuclear medicine(Ell 2014).
Figure 2. Binding energy per nucleon as a function of mass number.
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of the nuclear energy excess by γ photon emission is known 
as isomeric transition (IT). The emission of γ photons from 
the excited nucleus occurs immediately after α or β decay 
(within 10–12 s), but in some cases the nucleus may remain in 
the excited state for a measurable period of time with a half-
life in the range of 10– 9 s to several months. These longer-
lived metastable nuclei are called isomers and are designated 
with “m” after the mass number. Some metastable isomers 
have a half-life long enough for their chemical separation 
from the parent radionuclide. Such an example is Tc-99m, 
which is produced from Mo-99 in a technetium generator. 
Tc-99m undergoes de-excitation to its ground state isomer 
Tc-99 and during this process it emits a monoenergetic γ-ray 
of 140 keV:
Mo4299 Tc43
99mβ- IT Tc4399 + γ
An additional process via an excited nucleus can achieve 
the ground state is internal conversion (IC). Because the wave 
function of an orbital electron may overlap that of the excited 
nucleus, the excitation energy can be directly transferred to 
an orbital electron without the involvement of a γ photon. If 
an electron absorbs the nuclear energy this way, it is ejected 
from the atom, and it is called conversion electron. Internal 
conversion and isomeric transition are competing processes, 
and the ratio between the number of conversion electrons 
and the number of γ photons is called conversion coefficient. 
For clinical imaging procedures the high photon abundance 
(IT) is desirable.
Description of the kinetics of the radioactive 
decay
The definition of radioactivity refers the decay rate of a ra-
dioactive substance:
dN
dt = λ N−
where N is the number of radionuclides, λ is the propor-
tionality constant, called decay constant. If the original num-
ber of nuclei present at t= 0 s is N
0
, then integration yields
N= N0 e−λt
where N is the number of radioactive atoms remaining 
after time of decay, t. Since it is simpler to determine the 
disintegration rate than the number of radioactive atoms, the 
practical expression of the radioactive decay is
A= A0 e−λt and λ=
ln2
t1/2
where A
0
 is the original activity and A is the activity 
remaining after time of decay, t (Fig. 3). Originally, curie 
(Ci) was used as the basic unit of radioactivity, based on the 
disintegrations per second (dps) occurring in the quantity of 
radon gas in equilibrium with 1 g of radium. In 1950, the curie 
was redefined as 37 billion disintegrations per second (dps) 
regardless of its source or characteristics.
detection of ionizing radiation
The detection of radiation and the measurement of its in-
tensity and energy distribution are important for imaging, 
for the exact determination of the activity of the radiophar-
maceuticals, for dosimetry of irradiations, and for radiation 
protection. Excitation and ionization are the basic processes 
forming the physical basis of radiation detection, where 
light resulting from fluorescent de-excitation, fluorescence 
photons or charged particles are collected and measured 
by photomultiplier tubes, scintillation detectors and either 
gas-filled or semiconductor devices, respectively. In nuclear 
medicine, gas ionization and scintillation detectors are used 
for most purposes.
Gas ionization detectors
Gas-filled ionization detectors are ion chambers by principle. 
Ion pairs formed from the filling gas atoms or molecules 
by the passage of the ionizing radiation are separated in 
an electrical field, and electrons collected on the anode 
produce a pulse. Gas ionization detectors are characterized 
by the effects created at different field strength between the 
electrodes, because the pulse size depends both on the field 
strength and on the type of radiation (Fig. 4). In the ioniza-
Figure 3. Decay of F-18, Tc-99m and I-131 over time.
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tion region the rapid ions are not recombined and a satura-
tion region is reached where all the primary electrons are 
collected. Detectors working under these circumstances are 
called ionization chambers that are used in dosimetry and 
in determining high levels of radioactivity (e.g., multicurie 
Tc-99m generators, high-activity I-131 shipments). At higher 
field strength, electrons from the primary ionization receive 
sufficient acceleration to produce additional ionization. This 
multiplication process results in electrical pulses linearly 
proportional to the energy deposited in the detector by the 
passage of the radiation, and also different types of radiation 
can still be discriminated. Proportional counters operate in 
this region. Beyond the proportional region, the gas multipli-
cation becomes very high, and the size of the electrical pulses 
is independent of the initial ionization, and also independent 
of the type and energy of the radiation. Geiger-Müller (GM) 
counters which operate in this region have high sensitivity to 
different types of radiation. GM detectors are limited to use 
for measuring low levels of radiation, but are frequently used 
in nuclear pharmacy for monitoring personnel and radioactive 
contamination in work areas.
γ Particles are easily detected by ionization chambers 
as they produce great number of ions along a short path. 
The ionization and excitation effects of the β– particles are 
weaker than that of the α particles, and thus, their measure-
ment requires amplification. It is achieved by proportional 
or GM counters, or by scintillation counting. Gamma rays 
produce very low density ionization in gases, therefore they 
are counted by solid scintillation counting or with semicon-
ductor detectors.
Scintillation detectors
In scintillation counting, fluorescence photons are detected 
which are emitted during de-excitation of molecules excited 
by ionizing radiation. Both liquid and solid scintillation meth-
ods are applied in nuclear medicine and nuclear pharmacy. 
In liquid scintillation measurements the radioactive sample is 
dispersed in a solution of an organic scintillator. It provides 
highly efficient detection of β particles, but also used for 
the quantitative analysis of α, weak γ, X-ray and Auger e– 
emitters. The molecular interactions leading to photons are 
represented on Figure 5 including processes that decrease the 
counting efficiency in liquid scintillation counting.
Solid scintillation detectors typically use inorganic crys-
talline materials such as NaI(Tl), CsI(Tl) and Bi
4
Ge
3
O
12
. 
Tl-activated NaI crystals (NaI(Tl)) are the most commonly 
used solid scintillators for γ or X-ray photon measurements. 
The principal mechanisms of interaction between γ or X-ray 
photons and matter are photoelectric effect, Compton-effect 
and pair production, all of which provide electron – hole pairs 
in the crystal. These electrons and holes are trapped by Tl+ 
ions followed by radiative recombination of trapped electrons 
with free holes to form excited [Tl+]*. Light emission takes 
place upon the deactivation of [Tl+]*, and these light photons 
are detected by a PMT. NaI(Tl) is used for the detection of 
the 140 keV γ photons emitted by Tc-99m, the most widely 
used SPECT nuclide.
The principal image-forming detectors in nuclear medi-
cine are SPECT cameras and PET scanners. Hybrid systems 
combine these detectors with computed tomography (CT). 
The practical application of the detection of single photon 
emitting radionuclides has been developed after the introduc-
tion of the NaI(Tl) scintillation camera by Hal Anger (Anger 
1952). It consists of a large-area continuous NaI(Tl) crystal 
and an array of PMTs in combination with an absorptive 
collimator. This detector design provides spatial information 
on individual photon interactions and allows the creation of 
Figure 4. (A) Schematic representation of a gas-filled ionization detector. Electrons and cations are produced by the ionization of the filling gas 
exposed to ionizing radiation. Electrons collected by the anode produce a current which depends on the type and energy of the particle and 
also on the applied electric field. (B) The relationship between the pulse size produced and the potential applied across the electrodes.
A B
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two-dimensional images of the radiopharmaceutical distribu-
tion. Planar imaging of this type is called scintigraphy, and a 
typical example of this technique is bone scintigraphy. Such 
two-dimensional images recorded at multiple angles are 
reconstructed into a three-dimensional radiopharmaceutical 
distribution image in SPECT.
Positrons interact with matter similarly to electrons, but as 
the kinetic energy of the positron decreases, the probability of 
direct interaction with an electron increases in which both par-
ticles are annihilated. The energy of the two electron masses 
is converted into two photons with equal energy. The co-linear 
property of these photons allows them to be detected simulta-
neously by opposing detectors in coincidence (Fig. 6). These 
coincidence lines are processed by an image reconstruction 
algorithm to generate cross-sectional images of the activity 
distribution of the radiopharmaceutical. Because coincidence 
detection is used in PET, the application of collimators is not 
required, that in turn increases the detection sensitivity by a 
factor of 10 – 100 over SPECT cameras. Modern scanners 
have a resolution of 4–6 mm that is almost the physically 
possible maximal resolution. Common scintillators in modern 
PET scanners are BGO (Bi
4
Ge
3
O
12
), LSO (Lu
2
SiO
5
(Ce)) and 
GSO (Gd
2
SiO
5
(Ce)) with high light yield and fast responses 
during the detection of annihilation photons.
Production of radiopharmaceuticals
All radionuclides used in current nuclear medicine are pro-
duced artificially either in a nuclear reactor or in a particle 
accelerator by forcibly altering the nuclear structure of a 
stable target material. Currently ca. 80% of the medical ra-
dioisotopes are produced by neutron activation in a nuclear 
reactor, and the remaining isotopes are made by particle 
accelerators, mainly with cyclotrons. This ratio will be pre-
sumably changed, as cyclotrons offer many advantages over a 
nuclear reactor: (i) the volume of radioactive waste produced 
by cyclotrons is far less and less hazardous; (ii) the production 
is decentralized, i.e. the location of cyclotrons are hospital-
based, resulting in more secured delivery of pharmaceuticals 
to patients and excluding the risk of transport accidents; (iii) 
there is no need for controlled chain reactions, therefore 
Figure 6. Detection of annihilation photons in PET.
Figure 5. (A) Liquid scintillation in toluene solution in the presence of 
the scintillator 2,5-diphenyl-1,3-oxazole (POP). (B) Points of interfer-
ence caused by chemical, photon and color quench are indicated.
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there are no risk of nuclear-power accidents and nuclear 
proliferation.
Nuclear reactors used for isotope production have special 
ports where target materials can be introduced into the neu-
tron flux resulting in neutron activation of stable nuclides into 
radioactive isotopes. The (n,γ) reaction is a general nuclear 
reaction resulting in an isotope of the target nuclide (e.g. 
152Sm(n,γ)153Sm and 50Cr(n,γ)51Cr). If the product nuclide has 
a short half-life and decays to a longer-lived radionuclide, that 
can be isolated (e.g. 130Te(n,γ)131Te (γ–) 131I (t
1/2
(Te-131)= 25 
min, while t
1/2
(I-131)= 8 d). Fast neutrons can also be captured 
by target nuclei in an (n,p) reaction (32S(n,p)32P). This reaction 
is advantageous because the product nuclide can be separated 
from the target resulting in high specific activity products. 
Many radionuclides are isolated among the fission products 
of U-235 including Xe-133, I-131 and Mo-99.
In a cyclotron, charged particles are accelerated along 
a spiral path by a radiofrequency electric field, and the tra-
jectory is held fixed by a static magnetic field (Fig. 7). For 
nuclear medicine purposes two types of cyclotrons are used: 
positive ion instruments that accelerate protons and negative 
ion instruments that accelerate positronium ions (H–). Modern 
cyclotrons are positronium accelerators where the acceler-
ated H– ions pass through a carbon foil, which strips away 
electrons and the resulting protons are immediately used to 
bombard the target (e.g. 111Cd(p,n)111In and 18O(p,n)18F). Ra-
dionuclides produced this way are not isotopes of the target 
nuclide, therefore they can be separated by chemical methods 
and high specific activity products are obtained. If the product 
nuclide has a short half-life, e.g. in the case of PET agents, 
an on-site cyclotron is required.
In radiation therapy and diagnostic medicine it is pre-
ferred to use short-lived radionuclides, because it decreases 
the effective dose of the patients during imaging, and also 
eliminates the problem of residual radioactive waste disposal. 
A general solution is that a long-lived parent nuclide is stored 
and the short-lived daughter is isolated in the hospital as 
required for the nuclear medicine procedure. These systems 
are called radioisotope generators. A few appropriate nuclide 
pairs are summarized in Table 2. The most frequently used 
generator is based on the transient equilibrium of Mo-99 and 
Tc-99m (Fig. 8). The daughter nuclide Tc-99m is eluted by 
isotonic saline from an alumina column where the daughter 
Mo-99 is adsorbed. The resulting [99mTc]NaTcO
4
 solution is 
used for the preparation of Tc-99m radiopharmaceuticals that 
generally includes reduction of Tc(VII) with Sn(II) followed 
by complexation with different chelators.
dosimetry
Radiation protection uses the concept of effective dose that 
refers to the dose averaged over the entire body, and it takes 
into account the relative biological hazard of different types 
of radiation and also the relative sensitivity of different areas 
of the body. It allows for the quantification of health risk and 
also for the comparison of irradiation sources like natural 
Figure 7. Schematic diagram of a cyclotron.(Kowalsky et al. 2011) The 
trajectory of the accelerated particle is represented by a dashed spiral. 
Repeated application of accelerating voltages to ions by the hollow 
electrodes (dees) accelerates ions to high velocities.
Figure 8. Relative activity of Mo-99 and Tc-99m in the generator over 
time. Maximum buildup of Tc-99m activity is reached in ca 23 h fol-
lowed by elution.
Table 2. Common radionuclide pairs applied in generator 
systems.
Parent (t1/2) De-
cay
Daughter (t1/2) Decay Applica-
tion
Ge-68 (270 d) EC Ga-68 (68 min) β+ (1.9 MeV), EC PET
Rb-81 (4.5 h) EC Kr-81m (13 s) IT (191 keV γ) imaging
Sr-82 (25 d) EC Rb-82 (75 s) β+ (3.18 MeV) PET
Sr-90 (28.8 y) β– Y-90 (64 h) β– (2.28 MeV) therapy
Mo-99 (66 h) β– Tc-99m (6 h) IT (140 keV γ) imaging
Sn-113 (115 d) EC In-113m (1.7 h) IT (393 keV γ) imaging
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background radiation or nuclear medicine procedures (Table 
3). The effective dose is the sum of the equivalent doses in 
all organs and tissues weighted for the specific sensitivity of 
the organs and tissues. The equivalent dose is the radiation 
dose absorbed by an organ or tissue weighted for the type 
of radiation. Thus, the effective dose provides one number 
that reflects the whole body risk from non-uniform radiation 
exposure. The unit of the effective dose is sievert (Sv). The 
upper limit of the administration of a radiopharmaceutical 
is determined by these dose values, and the health risk of 
patients is also calculated from equivalent dose to individual 
organs and effective dose to the whole body values.
A major problem in radionuclide therapy is currently 
that there is no accepted standard method for calculating the 
absorbed dose from internal radionuclides. In an attempt to 
standardize dosimetry, the European Association of Nuclear 
Medicine (EANM) has recently issued a guidance document 
on ‘Good Practice of Dosimetry Reporting’, which makes 
recommendations for optimal internal dosimetry (Eberlein 
et al. 2011; Lassmann et al. 2011). At present, dosimetry in 
radionuclide therapy relies on the medical internal radiation 
dose (MIRD) formulation, which is based on the calculation 
of the average tumor-absorbed dose at a macroscopic level. 
This calculated dose assumes a homogenous distribution of 
radionuclides in organs, whereas spatial heterogeneity of 
internalized radionuclides exists at tissue and cellular levels 
(Brans et al. 2007). Heterogenic distribution of radionuclides 
leads to unevenly absorbed dose that may result in unsuccess-
ful radiotherapy.
The principles of tumor dosimetry for targeted therapy 
with internally administered radiopharmaceuticals are similar 
to those for external-beam radiation therapy (EBRT). The 
maximum absorbed radiation doses to critical organs are 
mostly related to experiences with EBRT. Dosimetry enables 
the conversion of the total number of radionuclide transfor-
mations in a particular source tissue to absorbed dose in a 
target tissue. Such conversion requires information on emis-
sion properties of the radionuclide as well as source-target 
tissue anatomy and composition. Monitoring toxicity allows 
physicians to reduce doses of repeatedly given radiopharma-
ceuticals though, “underdosing”, which may lead to lower 
efficacy, remains an important concern. The other important 
aspect is the prediction of tumor response and toxicity fol-
lowing radionuclide administration.
Dose quantities such as equivalent uniform biologically 
effective dose (EUBED), therefore, may be valuable comple-
ments to EBRT doses in targeted radiotherapy. With the cur-
rent advances in radiobiological modeling, it is conceivable 
that EUBED and tumor control probability calculations could 
routinely make part of patient-specific treatments in the future 
(Chianelli et al. 2011).
Radionuclide delivery systems, significance 
of formulation
In spite of the wide variety of radiolabelled agents that have 
been developed and applied clinically for the diagnosis and 
treatment of malignant conditions over the past decades, the 
number of diagnostic and therapeutic radiopharmaceuticals 
that has received approval for routine clinical use is very low 
(Dash et al. 2013). Since the design of selective radiothera-
peutic agents encounters multiple difficulties such as specific 
in vivo targeting of the tumor cells, clearance of radioactivity 
from non-target tissues and decay properties of the radionu-
clide, drug formulation and other derivatization strategies had 
to be developed (Aerts et al. 2014; Volkert et al. 1999).
Peptide and protein-based carriers
Chelate formation and/or subsequent chemo- or bioconjuga-
tion to transport molecules (peptides or proteins) is one of the 
most widely used formulation (e.g. Ga-68, Tc-99m, Sr-89, 
Y-90, In-111, Lu-177, At-211, Ac-225 or Ra-223 chelated 
by NTMP, EDTMP, DTPMP, DOTMP, NTA, EDTA, DTPA, 
DOTA) that serves for targeted delivery and enhanced spe-
cific radioisotope accumulation (Fig. 9) (Volkert et al. 1999). 
Beyond preventing isotope exchange, these chelators enable 
easy coupling of radionuclides to carriers and the resulting 
radiopharmaceuticals display improved pharmacodynamic 
and farmacokinetic characteristics (Attard et al. 1995; Jánoki 
et al. 1992; Volkert et al. 1991).
A series of radiolabelled peptides have been designed 
and optimized for tumor-targeted peptide receptor radionu-
clide therapy using the aforementioned complexes (Dong et 
al. 2014; Fani et al. 2012a; Okarvi 2008). Pre-clinical and 
clinical applications of this strategy have shown encouraging 
results on tumor response, overall survival, and quality of life 
Table 3. Average effective dose values of different procedures, activities.
Source of radiation exposure Effective dose
Radiation sickness > 1 Sv immediately
Coronary angiography 16 mSv
[67Ga]Ga-citrate (4 mCi) body scan 15 mSv
[18F]FDG (20 mCi) brain PET scan 14 mSv
Mammography (X-ray) 4 mSv
Natural background radiation (worldwide 
average)
2.4 mSv/y
Head CT 2 mSv
[123I]NaI (0.25 mCi) thyroid scan 1.9 mSv
[111In]pentetreotide (6 mCi) body scan 1.2 mSv
Dose limit for the general public 1 mSv/y
[133Xe]Xe (20 mCi) lung ventillation 0.5 mSv
Chest X-ray 0.1 mSv
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in patients with different tumors. Y-90-DOTA-TOC and Lu-
177 or Ga-68-DOTA-TATE radionuclide-chelate conjugates 
are the most common radiopharmaceuticals in detecting and 
targeting endocrine and neuroendocrine tumors (Bodei et al. 
2004; Bodei et al. 2013; Forrer et al. 2006; Haug et al. 2010). 
The Y-90, In-111 or I-131 labelled antibody- or octreotide-
based radiopharmaceuticals directed against the glycosylated, 
cell-surface phosphoprotein CD20 or somatostatin receptors, 
and that are used in the treatment of non-Hodgkin lymphoma 
and different neuroendocrine tumors, are further examples of 
this strategy (Kaltsas et al. 2005; Paganelli et al. 2002). In 
addition to the somatostatin analogs, other radiolabelled pep-
tides have also been developed for tumor cell overexpressing 
receptors such as integrin γVγ3, gastrin-releasing peptide re-
ceptor (GRPR), melanocortin-1 receptor (MC1-R), cholecys-
tokinin (CCK) receptor, and glucagon-like peptide-1 receptor 
(GLP-1R) (Dong et al. 2014; Fani et al. 2012a, 2012b).
Carrier-bound radioisotopes which bind cytoplasmic pro-
teins or nuclei of cancer cells, represent another diagnostic 
and therapeutic application. Cell-penetrating peptides are 
examples of such carriers that are capable of carrying radio-
isotopes into cells (Kersemans et al. 2008; van Duijnhoven et 
al. 2011). These peptides possess a short Arg-rich sequence 
that facilitates internalization of the radioisotope-peptide 
conjugate. Other members, such as the viral nuclear TAT 
protein and nuclear localizing peptides are able to deliver 
radionuclides or cell cycle control molecules into the nucleus 
where they can exert DNA damaging effects (Cornelissen et 
al. 2012a; Mishra et al. 2011). This latter approach proved 
to be advantageous for radionuclides that emit particles of 
extremely short path length (Auger electrons) and when 
incorporated or localized in close proximity to DNA (Hu et 
al. 2007).
Radionuclide conjugated circulating monoclonal antibod-
ies, antibody fragments are routinely used in radioimmuno-
therapy, diagnosis and tumor pre-sensitization strategies. 
Antibodies can recognize specific receptors and deliver high 
doses of radiation into tumor cells. These agents are directly 
radio-iodinated or chelated with macrocyclic chelators (i.e. 
DOTA) carrying the radionuclide that is often a β emitter such 
as Y-90 or I-131 (Forero et al. 2005; Reardon et al. 2002).
Nano-assemblies
Recent advances in nanotechnology has prompted the use 
of nanoparticles as carriers for radiotherapeutics. Inorganic 
multivalent nanoparticles that dispose of optical (e.g. gold 
nanoparticles, carbon nanotubes) or magnetic (e.g. iron oxide) 
properties, can be exploited for thermal-ablation therapy of 
malignant tumors or molecular imaging. As a result of their 
multivalency, other types of radiolabelled nanoparticles, 
composed of self-organizing materials have proven to be 
promising tools as multimodal imaging agents in the diag-
nosis and therapy of malignant processes (Ferro-Flores et al. 
2014; Xing et al. 2014).
Radiolabelled nanoparticles offer the potential for delivery 
of a large payload to tumors since nanoparticles tend to pas-
sively accumulate in tumors with disorganised vasculature 
(Goins 2008; Torchilin 2011). Liposomes loaded with Ac-225 
labelled trastuzumab have been shown to bind and internal-
ized into HER2/neu overexpressing cells (Sofou et al. 2007). 
Similarly, folate receptor targeting poly(lactate-co-glycolate) 
copolymer nanoparticles encapsulating docetaxel and Y-90 
radionuclide have been developed for the therapy of perito-
neal metastases in ovarian cancer (Werner et al. 2011). Other 
nanoparticle formulations such as dendrimers, carbon nano-
tubes, silica nanoparticles capable of directing therapeutic 
radionuclides into tumor cells have also been investigated (Di 
Pasqua et al. 2013; Hong et al. 2010; Ting et al. 2009). Car-
bon nanotubes covalently linked to anti-endothelial-cadherin 
antibody loaded with Zr-89 for PET imaging and with Ac-225 
for a particle therapy of a murine xenograft model of human 
colon carcinoma are further examples of this approach (Rug-
giero et al. 2010). Currently, the development and clinical trial 
of dual function “theranostic” nanoparticles for both imaging 
and radiotherapy are in progress (Xing et al. 2014).
Radiolabelled microspheres have been used for deliver-
ing localized radiation dose to tumors for different organs 
following intraarterial administration (Häfeli 2001; Muller 
et al. 1951). These microspheres have a size of ≥ 10-15 μm 
which is enough to lodge in the arterioles or capillaries of 
solid tumors having well-organized vasculature. Several types 
of particles and microspheres (Y-90 labelled-Y
2
O
3
 particles, 
Y-90 ceramic microspheres, Y-90 resin microspheres, and 
Y-90 glass microspheres) have been used with promising 
results, especially against liver malignancies (Deleporte et 
al. 2010; Harbert et al. 1987).
Figure 9. A representative model of a radionuclide-chelate-carrier 
conjugate. Depending on the radionuclide used, the complex can be 
applied for molecular imaging (PET) or radioimmunotherapy (RIT). 
The construct contains a chelated radionuclide which is bound to a 
carrier (peptide or antibody) that recognizes tumor antigens on the 
surface of cancer cells.
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diagnostic radiopharmaceuticals
Imaging procedures are non-invasive investigations that pro-
vide diagnostic information by measuring the distribution of 
radioactivity in the human body under normal and pathologi-
cal conditions. In nuclear medicine imaging the position of 
the radiation source within the body is detected, that is the 
fundamental difference from other imaging techniques, such 
as X-rays. In dynamic studies the rate of accumulation and 
clearance of the radiopharmaceutical are determined, while 
static imaging provide morphological information by detect-
ing the radioactivity accumulated in the organ of interest. 
Detection and measurement of organ radioactivity is generally 
performed with a gamma camera. In current clinical practice 
the most common imaging techniques (excluding X-rays) are 
computed tomography (CT), magnetic resonance imaging 
(MRI), ultrasound, planar scintigraphy, and single photon 
emission computed tomography (SPECT), positron emission 
tomography (PET) and magnetic resonance spectroscopy 
(MRS). Tomographic imaging (SPECT and PET) delineate 
high-resolution structural and functional information by 
constructing computer-generated transverse, sagittal and 
coronal slice images of an organ. Planar scintigraphy, CT, 
SPECT and PET make use of ionizing radiation, and except 
for CT, these imaging methods require the administration of 
medical radioisotopes. These tracers are generally short-lived 
radionuclides bound to chemical compounds which permit 
specific physiological processes to be investigated.
Positron emission tomography (PET) and its 
diagnostic use
With the recent advances in radiotracers and imaging tech-
niques PET has become one of the most powerful and revo-
lutionary methods in medical sciences and diagnosis. It is 
a high-spatial-resolution, sensitive and functional nuclear 
imaging technique that allows repeated in vivo non-invasive 
assessment and quantification of specific biochemical and 
physiological processes at molecular level (Clifford 2014; 
Mitterhauser et al. 2014). The principle of PET is based on the 
three-dimensional mapping and quantification of the distribu-
tion of a radiotracer that is labelled with a positron-emitting 
radioisotope (C-11, F-18, N-13, O-15, Cu-64, Y-86, Br-76, 
Ga-68, Rb-82 or I-124). It is usually introduced by injection 
and accumulates in the target tissue. As it decays it emits 
a positron, which combines with a nearby orbital electron 
resulting in the simultaneous emission of two gamma pho-
tons with the same kinetic energy (i. e. with the same tissue 
penetration property) in opposite directions. These photons 
are detected by the PET camera ring and the reconstructed 
images provide functional information on the target organ or 
tissue, on their metabolic activity, still before the anatomical 
signs of the disease are observed.
One of the most often used radionuclides for imaging pur-
poses is F-18 (Fig. 10). This may be due to its favorable physi-
cal (t
1/2
= 109.8 min) and nuclear characteristics, and also, to 
the successful use of [18F]fuoro-2-deoxy-D-glucose ([18F]
FDG) in diagnostic and clinical oncology (Cai et al. 2008; 
Dolle 2013; Miller et al. 2008). Metabolic glucose imaging 
has been the primary use of [18F]FDG. This imaging modality 
has been used for the measure of metabolic activity, mostly 
in neurodegenerative and cardiovascular diseases (Nasrallah 
et al. 2013; Palumbo et al. 2014). [18F]FDG is physiologi-
cally and homogeneously distributed thorough cerebral and 
peripheral tissues, and tumors are visualized as lesions with 
higher or lower radiopharmaceutical uptake, compared with 
normal parenchyma (Fig. 11) (Palumbo 2008).
In recent years, other radiopharmaceuticals more tumor-
selective than [18F]FDG have been developed. F-18 labelled 
choline analogues have been synthesized for the diagnosis of 
brain and prostrate cancers (Giovacchini et al. 2010; Treglia 
et al. 2012). Other F-18 labelled radiopharmaceuticals are 
O-(2-fluoroethyl)-L-tyrosine ([18F]FET) and 3,4-dihydroxy-
6-fluoro-L-phenylalanine ([18F]DOPA) (Chen 2007; Grosu et 
al. 2011). They have a brain tumor uptake similar to that of 
the [11C]Met (Chen 2007), with the advantage of a longer half-
life, with respect to C-11 labelled compounds. Kinetic studies 
have shown that Met has a significantly higher uptake in all 
cells examined, with respect to FET. Furthermore, inflam-
matory cells preferentially incorporate Met than tumor cells, 
while significantly higher FET uptake was assessed in tumor 
cells. [18F]DOPA has been used to image brain tumors due to 
high tumor uptake with respect to normal brain parenchyma 
(Pafundi et al. 2013). [18F]DOPA can be considered useful in 
investigating brain metastases for the ability to cross the blood 
brain barrier, the low distribution in normal gray and white 
matter and the high tumor to normal tissue ratios.
A further F-18 labelled radiopharmaceutical is 3’-deoxy-
3’-fluorothymidine ([18F]FLT) that is used to image cell prolif-
eration in vivo (Ullrich et al. 2008). [18F]FLT is phosphorilated 
by thymidine kinase 1 (TK1) and as a result it accumulates 
in the cell. Tumor cells have a higher rate of proliferation, 
therefore they have an elevated activity of TK1 compared to 
normal tissue, which leads to a higher rate of accumulation of 
[18F]FLT, which facilitates their detection using PET.
Figure 10. Structure of F-18 radiopharmaceuticals.
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C-11 (t
1/2
= 20.38 min) is another PET radionuclide, though 
routine work with this radionuclide requires a cyclotron on 
site. Despite this disadvantage, the interest for C-11 is more 
intense since C-11 labelling of compounds can give radiotrac-
ers with unchanged pharmacokinetics and pharmacodynamics 
(Miller et al. 2008; Roeda et al. 2007). In comparison with 
F-18, C-11 labelled radiotracers offer exploration of in vivo 
metabolic pathways, and are often used with F-18 labelled 
compounds in parallel. Chemically, C-11 methylation is by 
far the most versatile method for the introduction of C-11 
into radiopharmaceuticals, and radiolabelled reagents such as 
methyl-iodide ([11C]CH
3
I), methyl-triflate ([11C]CH
3
O(SO
2
)
CF
3
) and phosgene ([11C]COCl
2
 are most widely applied for 
this strategy (Nagren et al. 1995; Wuest 2007).
Single photon emission computer tomography 
(SPECT) and its diagnostic use
Although, positron-emitting radiopharmaceuticals represent 
the ideal in vivo biomarkers for tumor and metastasis imaging, 
gamma-emitting radiopharmaceuticals visualized by SPECT, 
are useful, since the production of the radiopharmaceutical 
does not require an on-site cyclotron. However, the resolu-
tion is lower as compared to PET. Organ malfunction can be 
indicated if the radionuclide is either partially taken up by an 
organ, or taken up in excess over a period of time (Palumbo 
et al. 2014; Sogbein et al. 2014). The most frequently used 
gamma-emitter is Tc-99m, and a large number of Tc-99m 
based radiotracers have been developed including sestamibi 
(Higley et al. 1993; Jones et al. 1984; Wackers et al. 1989), 
tetrofosmin (Platts et al. 1995), and teboroxime (Johnson 
et al. 1990). Sestamibi and tetrofosmin have seen wide-
spread clinical use, because they meet the requirements for 
myocardial perfusion, and a straightforward radiochemical 
synthesis and purification is available for them (Sogbein et 
al. 2014). In addition, [99mTc]tetrofosmin has been shown to 
accumulate intracellularly in actively proliferating cells, and 
thus, widely used as a neuro-oncological radiotracer in brain 
tumors (Palumbo et al. 2014).
Recently, more selective and potent Tc-99m complexes 
have been introduced and tested in therapy. These new agents 
contain cationic Tc-99m nitrido complexes, coordinating ei-
ther bidentate dithiocarbamate or tridentate bisphosphine-type 
chelates (Bolzati et al. 2002; Boschi et al. 2002; Boschi et 
al. 2003). These derivatives demonstrate high cardiac uptake, 
long-time retention and nearly complete elimination from 
hepatocytes of Sprague-Dawley rats. Their heart/liver ratios 
were found to be higher than that of the [99mTc]sestamibi.
A gamma-emitting radiopharmaceutical, [123I]-iodo-α-
methyl tryrosine, ([123I]IMT) was defined as a SPECT tracer. 
[123I]IMT shares similar properties with other positron-emit-
ting amino acid tracers, and is supposed to be incorporated via 
a stereo-selective active transport mechanism into neuronal 
cells (Palumbo 2008). Its uptake demonstrates relationship 
with cell proliferation and thus being applicable for the detec-
tion of malignancies of the central nervous system. Another 
I-123 labelled radiopharmaceutical is [123I]meta-iodobenzyl-
guanidine ([123I]mIBG), that is the most extensively studied 
norepinephrine analogue for SPECT imaging of heart failure 
and central nervous system diseases. It shares similarities 
with norepinephrine with respect of storage, reuptake and 
release in presynaptic sympathetic nerve terminal (Bristow 
et al. 1982; Jacobson et al. 2010; Verberne et al. 2008). Its 
I-131 labelled counterpart has long been used as a radiophar-
maceutical for the treatment of neuroblastomas.
Recent studies have shown that the PET radiotracer [18F]
FDG may be a more promising tool for the imaging of in-
flammation than the [99mTc]annexin-V conjugate, originally 
developed for the investigation of apoptosis with SPECT 
(Laufer et al. 2009). [18F]FDG is an inflammatory marker 
which accumulates in actively recruited and metabolically 
active leukocytes, specifically macrophages. This property 
can be specifically exploited for the imaging of the inflam-
matory processes of the coronaries (Rogers et al. 2010; Rudd 
et al. 2002).
Multimodality imaging
Noninvasive multimodality imaging is a combination of 
different modalities such as nuclear medicine and radiology 
that offers revolutionary opportunities in clinical practice. In 
synchronous multimodality imaging, which is by far the most 
effective imaging technique, morphological and functional 
information are merged and processed in time and space. 
Ideally, any multimodal imaging approach should provide a 
more exact localization, extent and metabolic activity of the 
target tissue, facilitating faster and more accurate diagnosis. 
Data interpretation is based on tissue blood flow or morpho-
Figure 11.  [18F]FDG PET showing metabolic differences in normal and 
pathological human brains. Orange areas show high glucose uptake 
and increased metabolism, while spreading dark spots indicate pro-
gressive neurodegeneration and cell death.
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logical and functional changes that indicate the presence of 
any disease (Marti-Bonmati et al. 2010).
There are many multimodal technologies, but the most 
commonly used are SPECT-CT, PET-CT, PET-MRI and 
functional MRI combined with near infrared spectroscopy. 
Although SPECT-CT and PET-CT are becoming standard 
practice, MRI imaging has advantages over PET, SPECT 
and CT. It provides better soft-tissue contrast and multi-
dimensional functional, structural and morphological in-
formation (Marti-Bonmati et al. 2010). The fMRI-NIRS 
modality is generally used for measuring tissue oxygenation/
deoxygenation (ischemic conditions). Recently, combination 
of functional MRI and magnetoencephalography (MEG) or 
two-dimensional electroencephalography (EEG), have been 
used successfully for the measurement of neural electrical 
activity. This approach may have significance in the research 
and diagnosis of neurodegenerative diseases (Czisch et al. 
2004; Martinez-Montes et al. 2004).
Therapeutic radiopharmaceuticals, targeted 
tumor therapy
Therapeutic procedures are either curative or palliative and 
essentially rely on the absorption of radiation to destroy dis-
eased tissue. Rapidly dividing cells are particularly sensitive 
to damage by irradiation. For this reason, some cancerous 
growths can be controlled or eliminated by irradiating the area 
containing the growth. External irradiation can be carried out 
using a γ beam from a Co-60 source, or using high-energy 
X-rays produced by linear accelerators. Treating leukaemia 
may involve a bone marrow transplant, when the defective 
bone marrow is killed off with a massive dose of irradiation 
followed by implanting healthy bone marrow from a donor. 
Internal radiotherapy is achieved by administering or plant-
ing a source of ionizing radiation, usually a γ or β emitter, 
in the target area. Ir-192 implants are used especially in the 
treatment of head and breast cancers. They are produced in 
wire form and are introduced through a catheter to the target 
area, and after administering the appropriate dose, the im-
plant wires are removed. This brachytherapy (short-range) 
procedure gives less overall radiation to the body, and is more 
localized to the target tumor.
α particle emitting radiopharmaceuticals and 
their therapeutic use
The use of α particle emitting isotopes, such as Bi-213, 
At-211, Ac-225, Th-227 and Ra-223 for targeted radiophar-
maceutical therapy has been the subject of intense research 
over the past decade. Due to their short pathlength, α particles 
can only traverse a few cells from the point of decay. Thus 
α-emitters are ideal for treating small-volume, homoge-
neous, disseminated cancer (Baidoo et al. 2013). Despite 
their advantageous radiochemical and radiopharmaceutical 
properties, the number of α particle emitting diagnostic and 
therapeutic drugs is much lower than those of the β particle 
emitting ones. The α  emitter [223Ra]RaCl (Alpharadin) and 
other Ra-223 containing radiopharmaceuticals have shown 
efficacy in castrate-resistant prostate and bone cancer (Shirley 
et al. 2014; Zustovich et al. 2014). Ra-223 mimics calcium 
depositing in skeletal tissue, and disposes low hematologic 
toxicity. At present, this radionuclide is the only drug that 
facilitates overall survival in patients with bone metastases 
and prostate cancer, and improves patient prognosis (Zus-
tovich et al. 2014).
A number of immune-conjugates that incorporate γ emit-
ters and DTPA or DOTA chelators, have shown therapeutic 
opportunities. For example, Bi-213 coupled to an anti-CD33 
antibody (HuM195, lintuzumab), was tested in a phase I 
clinical trial of patients with acute myeloid leukemia who 
had been pre-sensitized with cytarabine (Rosenblat et al. 
2010). In spite of their effectiveness and the new generation 
bifunctional Bi-212/213 derivatives that have been recently 
developed, the short half-life of the radionuclides and their 
slow complexation kinetics, remain an unsolved problem 
(Hassfjell et al. 2001). To overcome these issues, novel octa-
dentate chelator (4-[2-(bis-carboxymethyl-amino)-ethyl]-7-
carboxymethyl-acetic acid) (NETA) containing derivatives 
are being developed that have shown increased in vitro serum 
stability, biodistribution and tumor uptake in a preclinical 
study (Kang et al. 2013).
Another α emitter-containing radiotherapeutics, At-211 
labelled immune-conjugates have been synthesized and 
evaluated for their therapeutic potential (Zalutsky et al. 
2007, 2008). Since proteins labelled with At-211 by direct 
electrophilic astatination were unstable following in vivo ad-
ministration (Zalutsky et al. 1996), N-succinimidyl-3-[211At]
astatobenzoate (SAB) and other formulation strategies has 
been considered (Pozzi et al. 2005a; Pozzi et al. 2005b). The 
therapeutic potential and utility of MAbs and MAb fragments 
labelled with At-211 has been investigated in several MAb 
systems (Eriksson et al. 2013; Zalutsky et al. 2007). Although, 
studies on [211At]MAbs following intravenous administration 
demonstrate site-specific accumulation in tumors, increased 
levels of At-211 in normal tissues indicates rapid rates of At-
211 metabolism (radiolytic factors). In spite of this fact, the in 
vivo stability of radioimmuno-conjugates labelled with [211At]
SAB may be acceptable, particularly for non-intravenous 
applications.
An experimental development of the targeted γ therapy 
is the boron neutron capture therapy (Moss 2014) that uses 
B-10 which concentrates in malignant brain tumors. After 
administration of the B-10 containing pharmaceutical, that 
is the precursor of the α emitting radiopharmaceutical, the 
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patient is irradiated with thermal neutrons. These neutrons 
are strongly absorbed by B-10, producing high-energy α 
particles in an (n,α) reaction, which kill the cells where the 
B-10 containing precursor accumulated. The disadvantage of 
this procedure is that the patient is required to be brought to 
a nuclear reactor, rather than the radioisotopes being taken 
to the patient.
β Particle emitting radiopharmaceuticals and 
their therapeutic use
Radionuclides such as P-32, Cu-64/67, Sr-89, Y-90, Sn-117m, 
I-131, Rh-105, Ho-166, Lu-177 and Re-186/188 that decay 
by β emission are used most extensively for radiotherapeutic 
applications in current clinical practice (Volkert et al. 1999). 
β Particles produce a highly homogenous radiation dose, 
sparsely ionize molecules with a linear energy transfer value 
of about 0.2 keV/mm, and have a range of several millimeters 
in solid tissue. One consequence of this relatively long range 
is that radionuclides, especially with high energy electrons, 
are able to cross-fire neighbouring, non-targeted tissue 
components. This phenomenon proved to be particularly 
detrimental for tumors of the bone marrow since collateral 
irradiation of this tissue leads to myelosuppression and limits 
therapeutic application of high energy γγemitters (Bayouth 
et al. 1995; Johnson et al. 1992; Volkert et al. 1993). To 
circumvent this problem, a new concept, the combination of 
different isotopes with high (Y-90) and low (Lu-177) energy 
β emission, has proved to be a successful approach in the 
treatment of tumors and their micro-metastases in rat tumor 
models (de Jong et al. 2005).
The potential of radiolabelled antibodies, radioimmuno-
conjugates, to deliver a therapeutic dose of radiation to 
malignant cells has been particularly well documented in 
the case of lymphomas and neuroblastoma (Barbet et al. 
2012). Currently, two drugs, anti-CD20 antibodies labelled 
with Y-90 (ibritumomabtiuxetan; Zevalin) or I-131 (tositu-
momab; Bexxar) have shown efficacy in B-cell non-Hodgkin 
lymphoma (Witzig et al. 2011). These agents are also used as 
supplement following chemotherapy (Witzig 2013). Recently, 
other cell surface antigens, including the CD45, CD66 and 
CD33, have also been targeted with β-emitting radioimmuno-
conjugates for the treatment of haematological malignancies 
(Buchmann et al. 2009).
As has been shown, I-131 has a very high radiothera-
peutic potential for the treatment of malignant diseases such 
as gliomas, pheochromocytoma, and carcinoids. I-131 is 
commonly used to treat thyroid cancer, and also to treat non-
malignant thyroid disorders. It is also used for imaging and 
therapy of neuroblastomas (Wilson et al. 2014). Most neuro-
blastomas express a noradrenaline transporter that can take up 
[131I]meta-iodobenzylguanidine (mIBG), a structural analogue 
of norepinephrine (Rufini et al. 2013). Generally, [131I]mIBG 
doses used to vary between 100 and 200 mCi (3.7-7.4 GBq) 
and are administered intravenously for systemic therapy, pre-
sensitization for chemotherapy, consolidation with myeloab-
lative chemotherapy and minimal residual disease treatment 
with immune- and differentiation therapy. Its most significant 
therapeutic drawbacks are the radiation-induced bone mar-
row suppression and the low tumor to non-target ratio. To 
overcome these disadvantages, the use of At-211 has proved 
to be a successful approach. In vitro cytotoxic results with 
this analogue on three different neuroblastoma cell lines have 
suggested that [211At]mABG could be a good substitute of the 
mIBG analogue (Strickland et al. 1994).
The treatment of bone cancer has always been a challenge 
due to the concomitant bone marrow suppression present. 
From therapeutic viewpoint, [89Sr]SrCl
2
 (Metastron) and 
Sm-153 EDTMP (Quadramet) are the most widely used 
radiopharmaceuticals for metastatic bone cancers (Baczyk 
et al. 2007; McEwan et al. 1994). Nowadays, the use of [32P]
sodium orthophosphate and [32P]phosphate is only limited to 
a few cases, and are more important for myeloid bone cancer 
associated palliative therapy (Roberts, Jr. 1979; Tennvall et 
al. 2007). However, the use of P-32 conjugates has been 
emerged in the treatment of various malignant intracavitary 
tumors. Interestingly, the [32P]chromic phosphate colloid has 
been approved for the treatment of metastatic ovarian, renal 
and GI cancers in spite of the fact that this colloid does not 
really discriminate between tumorous and non-tumorous tis-
sue (Denis-Bacelar et al. 2013; Pattillo et al. 1995; Zubillaga 
et al. 1996). This drawback limits its widespread application, 
thus this colloid compound has been substituted with tumor-
specific antibodies labelled with I-131, Y-90 or Lu-177 that 
have higher selectivity for the target tissue (Deutsch et al. 
1993; Meredith et al. 1996).
The mechanism of action of these radiopharmaceuticals 
relies on reductive processes, trans-metallation or direct 
adsorption on the inorganic, hydroxyapatite component of 
the regenerating bone. The rate and extent of these reactions 
depends on the kinetic and thermodynamic stability of the 
complexes. Re-186 HEDP and Sn-117m DTPA radionuclide 
complexes are two other therapeutic agents that are used for 
the eradication of bone cancer. The Sn-117m DTPA chelate 
is an experimental radiopharmaceutical undergoing clini-
cal evaluation for the treatment of painful bone metastases 
(Pandit-Taskar et al. 2004). Re-186 HEDP is a potentially 
useful radiopharmaceutical as clinical studies have shown 
encouraging results in palliative therapy where an overall re-
sponse rate of 70% in painful bone metastases was measured 
(Lam et al. 2004; Syed et al. 2006).
Auger-electron emitting radionuclides and their 
therapeutic use
Radionuclides such as I-125, I-123 and In-111, which possess 
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abundance of protons and decay by electron capture, are well 
suited to targeted radiotherapy. They emit short-range (<1 
nm to a few mm), low-energy (<1 keV), high linear energy 
transfer (4 - 26 keV/mm) Auger electrons that cause intense 
energy deposition in a nanometer scale volume around the site 
of decay (Kassis 2011). Cross-fire events are limited and non-
specific radiotoxicity thus avoided. In general, Auger elec-
tron-emitting isotopes are most effective when incorporated 
into or localized in close proximity to DNA. Efficient systems 
for directing Auger electron-emitting isotopes specifically 
to the nuclei of cancer cells are being searched extensively 
(Cornelissen et al. 2010, 2012b; Lobachevsky et al. 2005; 
Smit et al. 2001). A potential for future therapeutic benefit 
in the administration of Auger electron-emitting isotopes has 
been suggested by only a small number of clinical studies. A 
combination of intrathecal [125I]5-iodo-2’-deoxuyridine ([125I]
IUdR) with methotrexate resulted in a fall in CA 19-9 tumor 
marker antigene, and clinical improvement in a patient with 
pancreatic cancer with meningeal metastases (Rebischung 
et al. 2008).
Tumor pre-targeting
Normal tissue toxicity, especially to the bone marrow is the 
major limiting factor in the application of radio-immuno-
therapy to solid tumors. Attempts have been made towards 
the improvement of biodistribution of radiopharmaceuticals, 
such as the use of a secondary antibody, local delivery or 
the use of metabolisable linkers. One of the approaches that 
facilitates high tumor uptake of therapeutic radionuclides and 
provides rapid clearance from blood and non-target tissues, 
is defined as “tumor pre-targeting” (Goldenberg et al. 2007; 
Sharkey et al. 2005). Several pre-targeting strategies have 
been worked out, but the most well known is based on the 
avidin/streptavidin biotin system (Casalini et al. 1997; Li et 
al. 2005; Wilbur et al. 2002). Since the early development of 
this approach many pre-targeting systems, such as bispecific 
anticancer antibodies with radiolabelled peptide haptens have 
been developed (Goldenberg et al. 2007). The avidin/strepta-
vidin biotin system is attractive since the affinity of avidin 
or streptavidin to biotin is very high. Pre-targeting uses a 
three-step approach wherein three reagents are administered 
sequentially in a protocol, designed to maximize the tumor 
radiation dose in the target tissue (Fig. 12).
The first step is a pre-sensitization of the target cancer 
cells with a long-lived, high affinity and specificity circulat-
ing non-radiolabelled MAb (e.g., avidin/steptavidin-MAb or 
bivalent MAb). Once the MAb construct has been localized 
in the tumor, a so called “chase molecule” is given in the 
second step at peak tumor uptake to eliminate the unbound 
MAb construct from the blood and other non-target tissues. 
The third step involves the administration of a radiolabelled 
(usually Y-90, I-131, Re-188 or Cu-67) hapten or biotin conju-
gate. Maximum tumor concentrations and tumor to non-target 
ratios are achieved in ca. 1-3 h. There is long-term retention 
of radioactivity associated with the streptavidin-MAb con-
jugate in the tumor (i.e., days), while the rapid elimination 
of unlocalized radioactivity attached to the small effector 
molecule, greatly reduces radiation dose to normal tissues 
(Schoffelen et al. 2013).
Summary and future perspectives
The patient outcomes resulting from the use of radiophar-
maceuticals have demonstrated the value of these agents in 
tumor diagnosis and in the treatment of diffuse, otherwise 
non-treatable conditions. Despite recent advances in biology, 
combinatorial-, peptide- and radiochemistry, only a limited 
number of radiolabelled drugs are used routinely for diagnosis 
and therapy. The greatest challenge associated with the design 
of novel radiolabelled compounds is the development of ra-
diolabelled conjugates that have the ability for selective tissue 
targeting and that meet the therapeutic requirements with an 
acceptable toxicity. Ideal therapeutic radiopharmaceuticals 
should locate at the tumor site, producing minimal or toler-
able radiation damage to normal surrounding tissues. It is 
difficult to achieve due to a variety of factors that are related 
to the chemical and physico-chemical characteristics of the 
radiopharmaceutical. The design of better radiotherapeutic 
agents, thus, requires optimization between specific in vivo 
targeting of the tumor and the clearance of radioactivity from 
non-target radiosensitive tissues as well as the decay proper-
ties of the radionuclide. The continuous radiopharmaceutical 
development is in progress because molecular imaging has 
enormous potential for early detection of diseases. Nowadays, 
multi-modality imaging, a combination of nuclear medicine 
and radiology, is beginning to gain widespread application. 
It offers not only more accurate diagnosis, but also facilitates 
personalized therapy and helps a better understanding of the 
underlying pathological processes.
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Nuclide t1/2 Decay Production Application
C-11 20.4 m β+ 0.96 MeV cyclotron In PET for studying brain physiology, pathology, for localising epileptic 
focus, and in dementia, psychiatry and neuropharmacology studies; also in 
cardiology; [18F]fluorodeoxyglucose (FDG) in cancer detection and in moni-
toring the progress of treatment, [18F]fluorothymidine (FLT), [18F]fluoromi-
sonidazole (FMISO), [18F]fluorocholine (FCH)
N-13 10.0 m β+ 1.19 MeV cyclotron
O-15 2.0 m β+ 1.72 MeV cyclotron
F-18 109.7 m β+ 0.64 MeV cyclotron
Na-24 15 h β– 1.39 MeV
γ 1.37, 2.75, 3.87 MeV
reactor electrolyte studies within the body
P-32 14.3 d β– 1.71 MeV reactor treatment of polycythemia vera (excess red blood cells) and essential throm-
bocyhtaemia, to treat bone pain from metastatic diseases
K-42 12.4 h β– 3.56, 1.97 MeV
γ 1.52, 0.31 MeV
reactor to study potassium distribution in body fluids; detection of brain tumors
Cr-51 27.7 d EC (320 keV γ) cyclotron red blood cell labelling for measuring their volume, survival and splenic 
sequestration; quantification of gastro-intestinal protein loss
Fe-59 44.5 d β– 1.57, 0.475, 0.273 MeV
γ 1.29, 1.09, 0.19, 0.14 MeV
reactor to study iron metabolism in the spleen, diagnosis of aplastic anemia, iron 
deficiency anemia, leukemia, and polycythemia
Co-57 271.6 d EC (136, 122, 14 keV γ) cyclotron diagnosis of pernicious anemia and defects of intestinal absorption
Co-60 5.27 y β– 315 keV
γ 1.33, 1.17 MeV
reactor sterilization
Cu-64 12.7 h EC (1.64 MeV γ)
β– 0.57 MeV
β+ 0.66 MeV
cyclotron to study genetic diseases affecting copper metabolism, e.g. Wilson’s and 
Menke’s diseases, and for PET imaging of tumors ([64Cu]ATSM), and tar-
geted therapy (Asabella et al. 2014)
Cu-67 62.0 h β– 577, 484, 395 keV
γ 185 and 92 keV
cyclotron targeted therapy (Asabella et al. 2014)
Ga-67 78.3 h EC (388, 296, 184, 93 keV γ) cyclotron SPECT tumor imaging (gallium citrate) for Hodgkin’s disease, lymphomas 
and bronchogenic carcinoma; localisation of acute inflammatory lesions
Ga-68 68.3 m β+ 1.90 MeV
EC (1.87, 1.24, 1.08, 0.80 
MeV γ)
genera-
tor (from 
Ge-68)
tumor imaging, especially leukocyte-derived malignancies by PET
Se-75 119 d EC (401, 280, 265, 136, 121, 
97, 66 keV γ; 14 keV e–; As K 
X-ray)
reactor investigation of the enterohepatic circulation of bile salts, diagnostic liver 
scanning (Boyd et al. 1981)
Kr-81m 13.1 s IT (191 keV γ) genera-
tor (from 
Rb-81)
imaging of pulmonary ventilation, early diagnosis of lung diseases and 
function
Rb-82 1.26 m β+ 3.18 MeV genera-
tor (from 
Sr-82)
myocardial perfusion PET imaging
Sr-89 50.5 d β– 1.49 MeV reactor palliative in prostate and bone cancer
Y-90 64.0 h β– 2.28 MeV reactor cancer brachytherapy, liver cancer therapy, for relieving the pain of arthritis 
in larger synovial joints
Tc-99m 6 h IT (140 keV γ) generator 
(from Mo-
99)
the most common diagnostic radioisotope for imaging the skeleton, heart 
muscle, brain, thyroid, lungs, liver, spleen, kidney, gall bladder, bone mar-
row, salivary and lacrimal glands, heart blood pool
Pd-103 17 d EC (498, 362, 297 keV γ; 43 
keV e–)
Rh K X-rays
reactor brachytherapy with sealed implants for early stage prostate cancer
In-111 2.83 d EC (247, 173 keV γ) cyclotron tumor imaging, platelet labelling, localization of inflammation, colon 
transfer studies
I-123 13.0 h EC (159 keV γ) cyclotron γ emitter without the beta radiation of I-131, thyroid gland imaging, treat-
ment of thyroid metastases, pheochromocytoma
I-124 4.15 d EC (1.69, 0.73, 0.61 MeV γ)
β+ 2.13, 1.53, 0.8 MeV
cyclotron PET imaging (Koehler et al. 2010)
I-125 60.2 d EC (35 keV γ)
18 keV e–
reactor prostate and brain cancer brachytherapy, determination of glomerular 
filtration rate, diagnosis of  deep vein thrombosis in the leg; widely used in 
radioimmuno-assays to measure hormone levels
I-131 8.04 d β– 806, 607, 336 keV, 10 keV 
e–
γ 637, 364, 284, 80 keV
32 keV Xe K X-ray
reactor blood volume/plasma volume determination; thyroid imaging, beta therapy 
of thyroid cancer; diagnosis of abnormal liver function, renal blood flow 
and urinary tract obstruction; treatment of refractory low-grade non-Hodg-
kin’s lymphoma
Appendix. Characteristics of medical radionuclides.
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Nuclide t1/2 Decay Production Application
Xe-133 5.2 d β– 346 keV
γ 81 keV, 36 keV e–
Cs K and L X-ray
reactor investigation of pulmonary function, lung ventilation imaging (Jones et al. 
1978)
Cs-137 30.1 y β– 1.18, 0.51 MeV
γ 662 keV
reactor low-intensity sterilization of blood
Sm-153 46.8 h β– 810, 710, 640 keV
γ 103, 70 keV
45 keV e–
Eu K and L X-rays
reactor palliative in osteoblastic metastatic bone lesions, treatment of prostate and 
breast cancer
Dy-165 2.3 h β– 1.31, 1.22 MeV
γ 716, 633, 361, 95 keV
52 keV Ho K X-ray
reactor synovectomy treatment of arthritis
Ho-166 2.8 h β– 1.85, 1.77 MeV
81 keV γ
diagnosis and treatment of liver tumors
Er-169 9.4 d β– 340, 332 keV
8 keV γ
reactor relieving arthritis pain in synovial joints
Yb-169 32.0 d EC (308, 198, 177, 131, 110, 63 
keV γ; 112 keV e–)
Tm K and L X-rays
cerebrospinal fluid studies in the brain
Lu-177 6.71 d β– 497, 384, 249, 175 keV
γ 208, 113 keV
15 keV e–
Hf K and L X-rays
reactor bone imaging, treatment of arthritis and neuroendocrine tumors (Kam et 
al. 2012)
Re-186 90.6 h β– 1.07, 0.93 MeV
γ 137, 122 keV
14 keV e–
W and Os K X-rays
reactor palliative in bone metastases, bone scintigraphy, radiosynovectomy (Ogawa 
et al. 2007)
Re-188 17 h β– 2.12, 1.97 MeV
γ 932, 633, 478, 155 keV
16 keV e–
Os K and L X-rays
genera-
tor (from 
W-188)
treatment of metastatic bone cancer, non-resectable liver cancer, non-mel-
anoma skin cancer, treatment of arthritis; inhibition of arterial restenosis 
following balloon angioplasty; endovascular radiation therapy
Ir-192 74.2 d β– 672, 536, 240 keV) EC (612, 
604, 589, 468, 317, 308, 296 
keV γ; 45 keV e–)
reactor internal source for cancer treatment
Tl-201 74 h EC (135, 167 keV γ; 48 keV e–) cyclotron diagnosis of coronary artery disease, heart muscle death, for location of 
low-grade lymphomas; the most common substitute for Tc-99 in cardiac-
stress tests
Pb-212 10.6 h β– 568, 331 keV
γ 300, 238 keV
74 keV e–
Bi K and L X-rays
generator 
(from Ra-
224)
targeted alpha immunotherapy (in vivo generates the α emitters Bi-212 and 
Po-212 ) for melanoma, breast and ovarian cancer (Milenic et al. 2005)
Bi-213 47 m α 5.8, 5.5 MeV
β– (8.4 MeV α from Po-213)
generator 
(from Ac-
225)
alpha immunotherapy, cancer therapy
